{"entity":{"id":"fcgr2a","kind":"target","name":"FCGR2A","aka":["Fc gamma receptor IIa","Low affinity immunoglobulin gamma Fc region receptor II-a","CD32","CD32A","IGFR2","CDw32","Fc-gamma-RIIa","FcgammaRIIa","FCG2","FCGR2A1","FCGR2"],"tldr":"FCGR2A (Low affinity immunoglobulin gamma Fc region receptor II-a) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.","summary":"Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens.\n\nCIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Trastuzumab.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:3616","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3616"},{"label":"UniProt P12318","url":"https://www.uniprot.org/uniprotkb/P12318/entry"},{"label":"NCBI Gene 2212","url":"https://www.ncbi.nlm.nih.gov/gene/2212"},{"label":"Ensembl ENSG00000143226","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143226"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["breast-cancer","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"FCGR2A","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:3616","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3616","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P12318","url":"https://www.uniprot.org/uniprotkb/P12318/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene FCGR2A","url":"https://civicdb.org/features/1842","note":"2 evidence items, 0 assertions, 2 variants; diseases: Breast Cancer, HER2 Positive Breast Cancer (GraphQL API, CC0)"}],"distribution":"one-type","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA FCGR2A: RNA tissue enhanced (lymphoid tissue 113 nTPM, placenta 127 nTPM); blood lineage lineage enriched (granulocytes 2,531 nTPM); high antibody staining in 2 normal tissues. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Breast cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas FCGR2A tissue","url":"https://www.proteinatlas.org/ENSG00000143226-FCGR2A/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000143226 associations","url":"https://platform.opentargets.org/target/ENSG00000143226/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:3616","ensembl":"ENSG00000143226","uniprot":"P12318","entrez":"2212","firstDescribed":1987,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Stuart S.G. et al, J. Exp. Med, 1987, \"Isolation and expression of cDNA clones encoding a human receptor for IgG (Fc gamma RII)\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/2824655/","biology":"Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonised antigens. Location: Cell membrane (UniProt). Locus 1q23.3 (HGNC).","whereFound":["Breast cancer: CIViC evidence names this disease","HER2-positive breast cancer: CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/fcgr2a/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}]}}